Pharmaceuticals & Therapeutics

Riding a wave of strong Q2 results, Supernus announces a merger of equals with Indivior, set to create a new, scaled player in CNS and addiction medicine.

A recall of a vital pet arthritis drug due to glass fibers reveals a history of quality control failures, forcing a difficult reckoning for pet owners and vets.

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

With Phase 3 results for Levosimendan imminent and its cash runway secured, Tenax Therapeutics faces a make-or-break moment in the PH-HFpEF space.

New patents in Europe and Australia grant Savara long-term protection for a vital new therapy, offering hope to patients with a rare, debilitating lung disease.

MIRA Pharmaceuticals moves two novel drug candidates closer to human trials, a key de-risking event for investors eyeing the massive pain and obesity markets.

Maia Fertility lands key VC funding to prove its Ferizyme™ platform in cattle, paving a strategic, data-driven path toward human reproductive medicine.

By assembling a 'dream team' of scientific advisors, INmune Bio isn't just advancing a drug; it's fortifying the very structure of cell therapy development.

As rising temperatures amplify India's public health risks, a new campaign tackles a persistent 'know-do gap' in dehydration treatment. But is consumer education enough?

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

Basking Biosciences' BB-031 targets a key clotting protein, dissolving clots hours later than current drugs. With a unique reversal agent, it could transform stroke care.

AB2 Bio's partnership with Nippon Shinyaku for Tadekinig alfa signals a new era for ultra-rare pediatric care and highlights a savvy biotech financing strategy.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

Octapharma's $1.5 billion Rock Hill facility promises 1,500 high-paying jobs. But beyond the local boom, it signals a critical shift in securing America's medical supply chain.

Clene Inc. heads to the Canaccord Growth Conference with promising ALS data and a clear regulatory path, but faces a critical test of investor confidence.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.

Qnovia secures a license for a novel peptide, D8, that kills superbugs differently. Can this university-born innovation turn the tide on antibiotic resistance?